Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
phenlarmide
- Development stage
- Phase 1
- Lead developer
- Yiling Pharmaceutical
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Phenlarmide (also known as FLZ) is an investigational small molecule drug developed for the treatment of Parkinson's disease. It has been studied in Phase 1 clinical trials to assess its safety, tolerance, and pharmacokinetics in humans. The drug is being developed by Shijiazhuang Yiling Pharmaceutical Co., Ltd (Yiling Pharmaceutical). While detailed information about its mechanism of action is not publicly available from current sources, it is under investigation for central nervous system disorders with a focus on movement disorders such as Parkinson's disease[7][10].
- Brand names
- phenlarmide
- Other names
- FLZphenlarmide tablets
Beyond the preview
Go deeper on phenlarmide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on phenlarmide.